[go: up one dir, main page]

PE20251587A1 - 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1 - Google Patents

1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1

Info

Publication number
PE20251587A1
PE20251587A1 PE2025000841A PE2025000841A PE20251587A1 PE 20251587 A1 PE20251587 A1 PE 20251587A1 PE 2025000841 A PE2025000841 A PE 2025000841A PE 2025000841 A PE2025000841 A PE 2025000841A PE 20251587 A1 PE20251587 A1 PE 20251587A1
Authority
PE
Peru
Prior art keywords
tautomer
alkyl
pharmaceutically acceptable
acceptable salt
cx3cr1
Prior art date
Application number
PE2025000841A
Other languages
English (en)
Inventor
Karolina Nilsson
Martin Bauer
Maria Olwegård-Halvarsson
Mikael Brink
Jon Paul Janet
Fredrik Bergstrom
Mateusz Piotr Plesniak
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20251587A1 publication Critical patent/PE20251587A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a compuestos moduladores de CX3CR1 de Formula (I) o una sal o tautomero farmaceuticamente aceptable de este, en donde R1 es alquilo C3-6 ramificado o cicloalquilo C3-6 ramificado; R2 es alquilo C1-3 o haloalquilo C1-3; m es 1 o 2; R3, R4 y R5 se seleccionan, independientemente de halo, alquilo C1-3, entre otros; el anillo A es fenilo, heteroarilo monociclico, entre otros; p es 0, 1, 2, 3, o 4. Tambien se refiere a una composicion farmaceutica que comprende el compuesto o una sal o tautomero farmaceuticamente aceptable de este. La administracion de una cantidad terapeuticamente efectiva de dicho compuesto, o de una sal o tautomero farmaceuticamente aceptable del mismo, permite tratar una enfermedad cardiovascular en una persona que padece o que esta en riesgo de desarrollarla.
PE2025000841A 2022-10-19 2023-10-18 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1 PE20251587A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263417472P 2022-10-19 2022-10-19
PCT/EP2023/079035 WO2024083933A1 (en) 2022-10-19 2023-10-18 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx 3cr1

Publications (1)

Publication Number Publication Date
PE20251587A1 true PE20251587A1 (es) 2025-06-16

Family

ID=88511235

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2025000841A PE20251587A1 (es) 2022-10-19 2023-10-18 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1

Country Status (17)

Country Link
US (2) US20240199558A1 (es)
EP (1) EP4605388A1 (es)
JP (1) JP2025537492A (es)
KR (1) KR20250086780A (es)
CN (1) CN120077035A (es)
AR (1) AR130808A1 (es)
AU (1) AU2023362450A1 (es)
CL (1) CL2025001155A1 (es)
CO (1) CO2025006339A2 (es)
CR (1) CR20250196A (es)
DO (1) DOP2025000096A (es)
IL (1) IL320305A (es)
MX (1) MX2025004633A (es)
PE (1) PE20251587A1 (es)
TW (1) TW202430188A (es)
UY (1) UY40495A (es)
WO (1) WO2024083933A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20251587A1 (es) * 2022-10-19 2025-06-16 Astrazeneca Ab 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1
WO2025219939A1 (en) * 2024-04-17 2025-10-23 Astrazeneca Ab Salts and polymorphs of cx3cr1 modulators
WO2025219950A1 (en) * 2024-04-18 2025-10-23 Astrazeneca Ab Small molecule cx3cr1 modulators

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19960683A1 (de) * 1999-12-15 2001-08-23 Aventis Cropscience Gmbh Substituierte 2,4-Diamino-1,3,5-triazine, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
JP2007507494A (ja) 2003-10-07 2007-03-29 アストラゼネカ・アクチエボラーグ ケモカイン受容体アンタゴニストとりわけＣＸ３ＣＲ１として有用な新規な２−置換４−アミノ−チアゾロ［４，５−ｄ］ピリミジン
GB0401269D0 (en) 2004-01-21 2004-02-25 Astrazeneca Ab Compounds
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
JP2010504963A (ja) 2006-09-29 2010-02-18 アストラゼネカ・アクチエボラーグ 新規な５，７−二置換された［１，３］チアゾロ［４，５−ｄ］ピリミジン−２（３ｈ）−アミン誘導体及び治療におけるその使用
AR071036A1 (es) 2008-03-26 2010-05-19 Astrazeneca Ab Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1.
TWI543975B (zh) 2011-09-13 2016-08-01 Eisai R&D Man Co Ltd Pyrrolidin-3-yl acetic acid derivatives
CA2894642A1 (en) 2013-01-08 2014-07-17 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
PE20251587A1 (es) * 2022-10-19 2025-06-16 Astrazeneca Ab 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1

Also Published As

Publication number Publication date
US20240383866A1 (en) 2024-11-21
CO2025006339A2 (es) 2025-05-29
KR20250086780A (ko) 2025-06-13
TW202430188A (zh) 2024-08-01
AU2023362450A1 (en) 2025-05-29
CL2025001155A1 (es) 2025-08-29
UY40495A (es) 2024-05-15
IL320305A (en) 2025-06-01
CR20250196A (es) 2025-11-21
MX2025004633A (es) 2025-06-02
JP2025537492A (ja) 2025-11-18
US20240199558A1 (en) 2024-06-20
WO2024083933A1 (en) 2024-04-25
EP4605388A1 (en) 2025-08-27
US12404253B2 (en) 2025-09-02
DOP2025000096A (es) 2025-07-15
AR130808A1 (es) 2025-01-22
CN120077035A (zh) 2025-05-30

Similar Documents

Publication Publication Date Title
PE20251587A1 (es) 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1
SA521430792B1 (ar) مركبات مضادة للفيروسات محتوية على نيتريل
PE20230238A1 (es) Inhibidores de kras g12c
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20211277A1 (es) Moduladores de profarmacos de la via de estres integrada
PE20251288A1 (es) Compuestos heterociclicos como inmunomoduladores
PE20250843A1 (es) Inhibidores macrociclicos de kras para el tratamiento de cancer
AR120682A1 (es) Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
PE20201202A1 (es) Inhibidores de cinasa dependientes de ciclina
AR061101A1 (es) Compuesto de fenil-triazolil- metoxi- arilo, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende
JPWO2019155399A5 (es)
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
PE20090435A1 (es) Inhibidores de tetrahidropiranocromeno de gamma secretasa
PE20090215A1 (es) Compuestos derivados de imidazopiridazinas como inhibidores de cinasa
RU2009117642A (ru) Применение спирооксиндоловых соединений в качестве терапевтических средств
PE20221461A1 (es) Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr
PE20131377A1 (es) Triazina-oxadiazoles
PE20231986A1 (es) Compuesto de heteroarilcarboxamida
PE20080895A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
RU2013119129A (ru) Органические соединения
PE20210478A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
EA200700756A1 (ru) Пиримидоны
PE20231847A1 (es) Compuestos fosfolipidos y usos de los mismos
EA201190119A1 (ru) ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ МАР-КИНАЗЫ p38
PE20252238A1 (es) Derivados de n-fenil-pirazolo[1,5-a] piridina-3-carboxamida como inhibidores de la c-kit quinasa de tipo salvaje para el tratamiento de la urticaria